Edition:
India

Five Prime Therapeutics Inc (FPRX.OQ)

FPRX.OQ on NASDAQ Stock Exchange Global Select Market

3.99USD
18 Oct 2019
Change (% chg)

$0.00 (+0.00%)
Prev Close
$3.99
Open
$4.04
Day's High
$4.09
Day's Low
$3.91
Volume
85,259
Avg. Vol
131,816
52-wk High
$14.41
52-wk Low
$3.22

Latest Key Developments (Source: Significant Developments)

Five Prime Therapeutics And Zai Lab Announce Exclusive License Agreement
Wednesday, 20 Dec 2017 

Dec 19 (Reuters) - Five Prime Therapeutics Inc ::FIVE PRIME THERAPEUTICS AND ZAI LAB ANNOUNCE EXCLUSIVE LICENSE AGREEMENT FOR FPA144 ANTI-FGFR2B ANTIBODY IN GREATER CHINA AND GLOBAL STRATEGIC DEVELOPMENT COLLABORATION.FIVE PRIME THERAPEUTICS - GRANTED ZAI LAB AN EXCLUSIVE LICENSE TO DEVELOP AND COMMERCIALIZE FPA144 IN GREATER CHINA TERRITORY​.FIVE PRIME THERAPEUTICS INC - ‍ZAI LAB WILL BE RESPONSIBLE FOR CONDUCTING PHASE 3 FIGHT TRIAL IN GREATER CHINA​.  Full Article

Bristol-Myers and Five Prime present early-stage data evaluating Cabiralizumab with Opdivo in patients with advanced solid tumors
Thursday, 9 Nov 2017 

Nov 9 (Reuters) - Five Prime Therapeutics Inc :Bristol-Myers Squibb and Five Prime present phase 1a/1b data evaluating Cabiralizumab (anti-csf-1 receptor antibody) with Opdivo (nivolumab) in patients with advanced solid tumors.Bristol-Myers Squibb - ‍Preliminary results show safety profile of Cabiralizumab plus Opdivo was generally consistent with that of Opdivo monotherapy​.Bristol-Myers Squibb - ‍Early efficacy signal observed in heavily pretreated patients with advanced pancreatic cancer with microsatellite stable disease​.Bristol-Myers Squibb Co - ‍Bristol-Myers Squibb is launching a new study of Cabiralizumab plus Opdivo​.Bristol-Myers Squibb Co - ‍Data show for first time that combining an anti-csf-1 receptor antibody with Opdivo may help restore t cell function​.  Full Article

Five Prime posts Q3 loss of $1.54 per share
Tuesday, 7 Nov 2017 

Nov 6 (Reuters) - Five Prime Therapeutics Inc :Five prime announces third quarter 2017 results and provides business update.Q3 loss per share $1.54.Q3 earnings per share view $-1.24 -- Thomson Reuters I/B/E/S.Five prime therapeutics inc - ‍collaboration revenue for q3 of 2017 increased by $1.6 million to $8.3 million​.  Full Article